Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis.

Abstract

Well designed pivotal clinical trials can provide robust evidence for the market authorisation of new cancer drugs, whereas lower-quality clinical evidence leads to uncertainty about drug benefits and harms. We aimed to investigate the strength of evidence supporting new cancer drug indications approved in China from 2017 to 2021. In this retrospective analysis, we searched publicly available data from the National Medical Products Administration website to identify pivotal pre-approval efficacy